Faster global financial news!
Amgen
-
Yahoo Finance analysis: Vertex Pharmaceuticals is a better healthcare stock buy than Amgen in 2026
The analysis highlights that Vertex Pharmaceuticals, with its dominant cystic fibrosis franchise and expansion into new disease areas like sickle cell disease, is growing faster and boasts superior op
-
Yahoo Finance Analysis: Amgen is a More Robust Healthcare Stock Investment Choice Than CRISPR Therapeutics in 2026
Yahoo Finance analysis suggests that in 2026, traditional pharmaceutical giant Amgen is a more stable investment choice compared to gene-editing pioneer CRISPR Therapeutics. The report indicates that
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
-
Yahoo Finance analysis: Vertex Pharmaceuticals is a better healthcare stock buy than Amgen in 2026
The analysis highlights that Vertex Pharmaceuticals, with its dominant cystic fibrosis franchise and expansion into new disease areas like sickle cell disease, is growing faster and boasts superior op
-
Yahoo Finance Analysis: Amgen is a More Robust Healthcare Stock Investment Choice Than CRISPR Therapeutics in 2026
Yahoo Finance analysis suggests that in 2026, traditional pharmaceutical giant Amgen is a more stable investment choice compared to gene-editing pioneer CRISPR Therapeutics. The report indicates that
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash
- No data
Amgen
24H Trending
-
1
Barclays: The First Wave of Physical AI Disruption May Not Be Humanoid, Specialized Robots Are Superior
-
2
UBS raises AI capital expenditure forecast: Nearing $1 trillion by 2026, with 90% of the increase driven by memory price hikes
-
3
Barclays: Humanoid robot computing power demand is mainly concentrated in edge AI, with limited but significant incremental growth for data centers.
-
4
OpenAI's new model, Astra, has captured 13% of enterprise AI spending within two weeks of its launch, prompting Anthropic to consider an early release of its new model to compete.
-
5
The dollar had its strongest week since June after the Federal Reserve's rate hike, with the Bloomberg Dollar Spot Index rising 1.1% this week.
-
6
Citibank Analysis: The Bank of Japan's dovish dissent and the Federal Reserve's rate hikes will accelerate its rate-hiking process, bringing forward the terminal rate achievement to July 2027.
-
7
Lookonchain Monitoring: A whale associated with Matrixport deposited 1,000 BTC, worth $81.06 million, to Binance.
-
8
Musk retweeted a post, stating that OpenAI's AI agent cheated and successfully escaped from a "safety sandbox," then attempted to cover its tracks.
-
9
Barclays: Mass Deployment of General-Purpose Humanoid Robots May Be Delayed Until Around 2035, with Intelligence, Not Hardware, Being the Bottleneck
-
10
CNBC reports: Nations and corporations are investing in underwater technology to address a "new arms race" for critical subsea infrastructure.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
